Plecanatide vs Cotadutide
Head-to-head comparison of Plecanatide (Plecanatide) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Cotadutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | Approx. 1620 Da | ~4,700 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | Approximately 24 hours |
| Amino Acids | 16 | 37 |
| Typical Dose | 3 mg once daily | 0.3-3 mg daily in clinical studies |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 18 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.